DifGen Pharmaceuticals LLC Receives USFDA Approval for Fluorometholone Ophthalmic Suspension, 0.1% – Expanding Its Complex Generic Portfolio
MIRAMAR, Fla., Feb. 12, 2026 /PRNewswire/ -- DifGen Pharmaceuticals, a leading US based generic pharmaceutical company, today announced that it has...
Read moreDetails